However, through our systematic review and meta-analysis, we got a more unified conclusion that CD3+, CD4+, CD8+, and Foxp3+ could serve as prognostic biomarkers in hepatocellular carcinoma. This evidence concerns the gene CD4 and hepatocellular carcinoma.